Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants
Authors:
Open Access
- 23 April 1998
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 21 (9) , 923-926
Abstract
We conducted a retrospective review of 125 patients undergoing high-dose therapy and stem cell rescue in order to evaluate the incidence of documented infection and the utility of the administration of vancomycin empirically. All patients received prophylactic oral quinolone therapy. Because neutropenia in this setting is relatively brief, 21 patients never manifested fever, and no patient died of infection. Of the remaining 104 patients, positive blood cultures were obtained in only 10, nine with a gram stain positive and one with a gram stain negative organism. Sixty-two patients without any evidence of gram positive infection received vancomycin according to the existing algorithm for care of neutropenic fevers. In this population of patients, empiric administration of vancomycin for neutropenic fevers without culture documentation appears to be unnecessary, could be discontinued safely and at substantial cost savings, and might slow the appearance of vancomycin-resistant organisms.Keywords
This publication has 10 references indexed in Scilit:
- Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem.Journal of Clinical Oncology, 1995
- Empiric therapy for infections in the febrile, neutropenic, compromised hostMedical Clinics of North America, 1995
- Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support.Journal of Clinical Oncology, 1994
- Infectious Morbidity Associated with Long-Term Use of Venous Access Devices in Patients with CancerAnnals of Internal Medicine, 1993
- Management of Fever in Patients with Cancer and Treatment-Induced NeutropeniaNew England Journal of Medicine, 1993
- Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective studyAntimicrobial Agents and Chemotherapy, 1992
- Vancomycin, Ticarcillin, and Amikacin Compared with Ticarcillin-Clavulanate and Amikacin in the Empirical Treatment of Febrile, Neutropenic Children with CancerNew England Journal of Medicine, 1988
- Gram-Positive Infections and the Use of Vancomycin in 550 Episodes of Fever and NeutropeniaAnnals of Internal Medicine, 1988
- Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemiaThe American Journal of Medicine, 1986
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaAnnals of Internal Medicine, 1966